BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31646745)

  • 21. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
    Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.
    Katayama A; Bandoh N; Kishibe K; Takahara M; Ogino T; Nonaka S; Harabuchi Y
    Clin Cancer Res; 2004 Jan; 10(2):634-40. PubMed ID: 14760086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
    Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
    Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas.
    Kumamoto H; Yamauchi K; Yoshida M; Ooya K
    J Oral Pathol Med; 2003 Feb; 32(2):114-20. PubMed ID: 12542835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium.
    Freitas S; Meduri G; Le Nestour E; Bausero P; Perrot-Applanat M
    Biol Reprod; 1999 Oct; 61(4):1070-82. PubMed ID: 10491646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.
    Shi Y; Parhar RS; Zou M; Hammami MM; Akhtar M; Lum ZP; Farid NR; Al-Sedairy ST; Paterson MC
    Br J Cancer; 1999 Mar; 79(7-8):1234-9. PubMed ID: 10098765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
    He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
    Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
    Yang HK; Jeong KC; Kim YK; Jung ST
    Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
    Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
    Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
    Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
    Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer.
    Shim KN; Jung SA; Joo YH; Yoo K
    J Gastroenterol; 2007 Feb; 42(2):120-8. PubMed ID: 17351800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
    Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
    Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases.
    Sato T; Sakai T; Noguchi Y; Takita M; Hirakawa S; Ito A
    Gynecol Oncol; 2004 Jan; 92(1):47-56. PubMed ID: 14751137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
    Wan Y; Wei Q; Pan Y; Liu Y
    Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):510-3. PubMed ID: 11832095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.